ICOS and neoplasm: By contrast, ICOS antibody treatment decreased T regulatory cells in the tumor when used as a single agent and also in combination with RT (ICOS Ab vs. Isotype p < 0.01; RT + ICOS Ab vs. RT p < 0.01), in line with the reported Treg depletion activity of this antibody in preclinical studies35.